#Abstr 0542 ASAS EULAR Recommendations for Management of axSpA 'Absence of response to treatment should prompt re-evaluation of the diagnosis and consideration of the presence of comorbidities.' @RheumNow #ACR22

18mo data of ARIAA study (6mo ABA in pre-RA): 12mo after discontinuation Progression to RA ABA 35% vs PBO 57% p=0.008 Improvement in synovitis, osteitis & tenosynovitis ABA 57% vs. 29% PBO Enough to move into clinical application? https://t.co/2CDN9M31mB Abs#0530 #ACR22 @Rheumnow https://t.co/R54AokGSiK

• Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Mo…

Jayne et al. ADVOCATE avacopan trial sub-analysis looking at patients eGFR<=20. Significantly better reduction albuminuria and increase eGFR. Numerically better recovery, lower GC, less infection @RheumNow #ACR22 Abstr#0525 https://t.co/v4ffiqfsyt https://t.co/9pK0Pn6IOj

• Recovery of Renal Function Among ANCA-Associated Vasculitis Patients with Basel…

🔎Look! Urinary biomarkers vs. UPCR in tx response of #lupus nephritis by Dr @andreafava et al 🦋A decline in several urinary BMs at 3 mos outperformed UPCR in predicting the 1 yr response. Urinary BMs as surrogate endpts in trials?🤔#ACR22 @RheumNow ABST0536 https://t.co/kMWmsK8mnO

@GuyKatzMD @zach_wallace_md et al. Hypocomplementemia seen in 30% IgG4-RD. More organs involved (mean 4.3 vs 2.9). More likely to have serum IgG4 above ULN (89%vs74%) and 5XULN (52%vs28%) @rheumnow #ACR22 Abstr#0144 https://t.co/bVRTuh3dsU https://t.co/3SHEbg2tbR

• The Association of Hypocomplementemia with Organ Involvement and Serum IgG4 in …

Sanchez-Bilbao et al. IV vs SC tocilizumab in 471 GCA patients. No differences in sustained remission or glucocorticoid-sparing. Numerically more AEs in IV but this due to longer follow up, no difference when corrected @rheumnow #ACR22 Abstr#0146 https://t.co/EB2RMYdzAr https://t.co/4xIMH1PIt3

• Intravenous versus Subcutaneous Tocilizumab in a Series of 471 Patients with Gi…

Fussner @LynnFussner et al. DAH in PEXIVAS. DAH more freq younger, PR3+, relapsing, higher disease activity, higher creatinine. DAH more likely to die at 30 days and 1 year than those without DAH @RheumNow #ACR22 Abstr#0526 https://t.co/XGYHvDkVeA https://t.co/IEOcQHEQ3e

• Characteristics and Outcomes of Participants with and Without Diffuse Alveolar …

Normal weight PsA pts had numerically better PsAID and PGA scores than obese PsA pts when treated with SEC. SEC was effective in all BMI subgroups. Abs 0395 #ACR22 @RheumNow https://t.co/oBSsuJKRem https://t.co/BhybOk76Gr

• How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Pa…

Werth et al. Lenabasum phase 3 trial indermatomyositis. Primary endpoint (TIS week 28) not met. Subgroup analysis suggest small effect on muscle and modest effect on skin disease @rheumnow #ACR22 Abstr#0173 https://t.co/qhL2PcTcHV https://t.co/uR8Bg5awiK

• Cutaneous Manifestations, Clinical Trials, Safety Efficacy and Safety of Lenaba…

Vikse et al. Norwegian case series of 40 patients treated with RTX for IgG4-RD. Efficacy across phenotypes 80-100% for improvement but only 45-78% for remission. @rheumnow #ACR22 Abstr#0147 https://t.co/J7b47ywbt0 https://t.co/pfhOIG5qXk

• Rituximab in IgG4-Related Diseae: An Open-Label Non-Randomized Observational St…

This work can lay foundation to so much more! #ArtificialIntelligence and #naturallanguageprocessing on Facebook private #gout groups - Mental health mentioned in 4% of all posts/comments - primary care asso with “trust” and urgent care with “fear” @RheumNow #ACR22 abst#0201 https://t.co/fSuOeNGWvg

Liew @rheum_cat et al. No evidence of cardioprotective effect of early initiation of TNFi in AxSpA. In fact seemed to be associated higher risk! CVD (HR 1.17), stroke (HR 1.24), and MACE (HR 1.22) @rheumnow #ACR22 Abstr#0415 https://t.co/a9lpxQuMB9 https://t.co/GdGfYxcAH6

• The Association of Early TNF Inhibitor Use with Incident Cardiovascular Events …

Germano et al. Physical exam of temporal arteries predictive of TAB+. Decreased pulse nad thickened artery most useful @rheumnow #ACR22 Abstr#0483 https://t.co/NGvu8pMiaj https://t.co/F0Y9oy0hWy

• Giant Cell Arteritis: Physical Examination of the Superficial Temporal Arteries…

Merkel. Vilobelimab in AAV. C5a mab. Phase 2. Given with RTX/CYC. Various steroid regimes (none, reduced, standard). Not powered for non-inferiority but encouraging results. Makes sense, this is the same pathway as avacopan @RheumNow #ACR22 Abstr#0524 https://t.co/HY5i6wqnjI https://t.co/CTXUdP3PZV

• A Randomized, Double-Blind, Phase II Study of Glucocorticoid Replacement by Vil…

Exciting development in Lupus! Change in urinary biomarkers (CD163 and MMR) better predictor than proteinuria for lupus nephritis treatment response. Larger longitudinal studies needed. Abs#0536 @RheumNow #ACR22 #ACRBest https://t.co/MLSWdl0xUo